Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1781149 | 0.82 | MGAM (0.39) | — | |
| SCHEMBL1780685 | 0.82 | MGAM (0.39) | — | |
| SCHEMBL1781151 | 0.82 | MGAM (0.39) | — | |
| SCHEMBL4750606 | 0.76 | SELP (0.34) | — | |
| SCHEMBL9988845 | 0.76 | SELP (0.34) | — | |
| SCHEMBL19818078 | 0.76 | SELP (0.34) | — | |
| SCHEMBL27386943 | 0.76 | SELP (0.34) | — | |
| SCHEMBL17866933 | 0.76 | CETP (0.44) | — | |
| SCHEMBL1979198 | 0.76 | SELP (0.34) | — | |
| SCHEMBL119608 | 0.75 | TYR (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 962 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333465-A1 | EFFECTIVE TRUNCATED PACAPS FOR DISEASE MODIFYING TREATMENT OF NEURODEGENERATIVE DISEASES | UNIV ARIZONA (US) | 2025-10-30 | — | — | US | claimed |
| US-20240352075-A1 | PACAP1-23 ANALOG GLYCOPEPTIDES AND METHODS FOR PRODUCING AND USING THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-10-24 | — | — | US | claimed |
| US-20240294595-A1 | GLYCOPEPTIDES AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2024-09-05 | — | — | US | claimed |
| EP-4392045-A1 | IRON COMPOSITIONS AND METHODS OF MAKING AND USING THEM | American Regent, Inc. (US) | 2024-07-03 | — | — | EP | claimed |
| US-11759456-B2 | Pharmaceutical composition | KOWA COMPANY, LTD. (JP) | 2023-09-19 | — | — | US | claimed |
| US-20230084291-A1 | IRON COMPOSITIONS AND METHODS OF MAKING AND USING THEM | AMERICAN REGENT, INC. (US) | 2023-03-16 | — | — | US | claimed |
| WO-2023028252-A1 | IRON COMPOSITIONS AND METHODS OF MAKING AND USING THEM | AMERICAN REGENT, INC. (US) | 2023-03-02 | — | — | WO | claimed |
| WO-2022272091-A1 | PACAP1-23 ANALOG GLYCOPEPTIDES AND METHODS FOR PRODUCING AND USING THE SAME | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2022-12-29 | — | — | WO | claimed |
| US-20200290038-A1 | PREFILLED CARTRIDGE | MYCARTIS N.V. (BE) | 2020-09-17 | — | — | US | claimed |
| US-20200147209-A1 | ALUM-CONTAINING COATING FORMULATIONS FOR MICRONEEDLE VACCINE PATCHES | KINDEVA DRUG DELIVERY L.P. | 2020-05-14 | — | — | US | claimed |
| US-20050090009-A1 | Compositions of stabilized DNA for coating microprojctions | ALZA CORPORATION | 2005-04-28 | — | — | US | claimed |
| US-20050049549-A1 | Method and device for enhancing transdermal agent flux | ALZA CORPORATION | 2005-03-03 | — | — | US | claimed |
| WO-2005016440-A1 | METHOD AND DEVICE FOR ENHANCING TRANSDERMAL AGENT FLUX | ALZA CORPORATION (US) | 2005-02-24 | — | — | WO | claimed |
| WO-2005016441-A1 | METHOD AND DEVICE FOR ENHANCING TRANSDERMAL AGENT FLUX | ALZA CORPORATION (US) | 2005-02-24 | — | — | WO | claimed |
| US-20050037996-A1 | Synthesis of high molecular weight iron-saccharidic complexes | CHROMACEUTICAL ADVANCED TECHNOLOGIES INC (US) | 2005-02-17 | — | — | US | claimed |
| US-20050031676-A1 | Method and device for enhancing transdermal agent flux | ALZA CORPORATION | 2005-02-10 | — | — | US | claimed |
| WO-2005000210-A2 | SYNTHESIS OF HIGH MOLECULAR WEIGHT IRON-SACCHARIDIC COMPLEXES | CHROMACEUTICAL ADVANCED TECHNOLOGIES, INC. (US) | 2005-01-06 | — | — | WO | claimed |
| WO-2004032971-A1 | PHARMACEUTICALLY ACTIVE OLIGOSACCHARIDE CONJUGATES | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2004-04-22 | — | — | WO | claimed |
| WO-2004033424-A1 | WATERSOLUBLE PRODRUGS OF PROPOFOL | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2004-04-22 | — | — | WO | claimed |
| EP-0653438-A2 | Oligonucleotide compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-05-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11759456-B2 | Pharmaceutical composition | PEF1, FIBP, F2 | CA1 3778/4885CA2 1496/4885CA9 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.